Background Age-related immunosenescence may impair the immune response to
vaccination in older adults. Adjuvanted influenza vaccines are designed to overcome …

MF59®-adjuvanted trivalent inactivated influenza vaccine (aIIV3) and high-dose trivalent
inactivated influenza vaccine (HD-IIV3) elicit an enhanced immune response in older adults …

Background Adults≥ 65 years of age have suboptimal influenza vaccination responses
compared to younger adults due to age‐related immunosenescence. Two vaccines were …

Background The effectiveness of standard, egg-derived quadrivalent influenza vaccines
(IIV4) may be reduced in adults≥ 65 years of age, largely because of immunosenescence …

Objective To assess the long-term safety of MF59-adjuvanted trivalent influenza vaccine
(aIIV3; Fluad™) in adults≥ 65 years of age. Methods Data from 36 primary vaccination and …

Background Clinical evidence supports use of enhanced influenza vaccines in older adults.
Few economic outcome studies have compared adjuvanted trivalent inactivated (aIIV3) and …

The burden of influenza is disproportionally higher among older adults. We evaluated the
relative vaccine effectiveness (rVE) of adjuvanted trivalent (aIIV3) compared to high-dose …

Background Approximately 50 000 influenza-associated deaths occur annually in the United
States, overwhelmingly among individuals aged≥ 65 years. Although vaccination is the …

Traditional influenza vaccines may be less immunogenic in adults≥ 65 years of age due to
immunosenescence. Two influenza vaccines—MF59®-adjuvanted trivalent inactivated …

Background The mammalian cell-based quadrivalent inactivated influenza vaccine (IIV4c)
has advantages over egg-based quadrivalent inactivated influenza vaccine (IIV4e), as …